Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

915 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of wildtype Merkel cell polyomavirus genomic sequence and VP1 transcription in a subset of Merkel cell carcinoma.
Kervarrec T, Appenzeller S, Tallet A, Jullie ML, Sohier P, Guillonneau F, Rütten A, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Beneton N, Bens G, Nardin C, Aubin F, Dinulescu M, Visée S, Herfs M, Touzé A, Guyétant S, Samimi M, Houben R, Schrama D. Kervarrec T, et al. Among authors: blom a. Histopathology. 2024 Jan;84(2):356-368. doi: 10.1111/his.15068. Epub 2023 Oct 13. Histopathology. 2024. PMID: 37830288
Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma.
Durand MA, Drouin A, Mouchard A, Durand L, Esnault C, Berthon P, Tallet A, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Saiag P, Beneton N, Bens G, Nardin C, Aubin F, Dinulescu M, Collin C, Fromont-Hankard G, Cribier B, Laurent-Roussel S, Cokelaere K, Houben R, Schrama D, Peixoto P, Hervouet E, Bachiri K, Kantar D, Coyaud E, Guyétant S, Samimi M, Touzé A, Kervarrec T. Durand MA, et al. Among authors: blom a. J Invest Dermatol. 2023 Oct;143(10):1937-1946.e7. doi: 10.1016/j.jid.2023.02.038. Epub 2023 Apr 8. J Invest Dermatol. 2023. PMID: 37037414
Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma.
Samimi M, Benlalam H, Aumond P, Gaboriaud P, Fradin D, Kervarrec T, Florenceau L, Vignard V, Blom A, Touzé A, Gervois N, Labarriere N. Samimi M, et al. Among authors: blom a. Cell Immunol. 2019 Oct;344:103961. doi: 10.1016/j.cellimm.2019.103961. Epub 2019 Aug 1. Cell Immunol. 2019. PMID: 31472938
Merkel Cell Polyomavirus‒Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation.
Kervarrec T, Appenzeller S, Samimi M, Sarma B, Sarosi EM, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Benethon N, Bens G, Nardin C, Aubin F, Dinulescu M, Jullie ML, Pekár-Lukacs Á, Calonje E, Thanguturi S, Tallet A, Wobser M, Touzé A, Guyétant S, Houben R, Schrama D. Kervarrec T, et al. Among authors: blom a. J Invest Dermatol. 2022 Mar;142(3 Pt A):516-527. doi: 10.1016/j.jid.2021.07.175. Epub 2021 Sep 1. J Invest Dermatol. 2022. PMID: 34480892 Free article.
Investigation of the RB1-SOX2 axis constitutes a tool for viral status determination and diagnosis in Merkel cell carcinoma.
Thanguturi S, Tallet A, Miquelestorena-Standley E, Coco C, Le Corre Y, Hainaut-Wierzbicka E, Blom A, Saiag P, Beneton N, Bens G, Zaragoza J, Nardin C, Aubin F, Dinulescu M, Machet MC, Houben R, Schrama D, Collin C, Fromont G, Jullie ML, Macagno N, Gaboriaud P, Berthon P, Touzé A, Guyétant S, Samimi M, Kervarrec T. Thanguturi S, et al. Among authors: blom a. Virchows Arch. 2022 Jun;480(6):1239-1254. doi: 10.1007/s00428-022-03315-6. Epub 2022 Apr 12. Virchows Arch. 2022. PMID: 35412101
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma.
Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Ødum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC. Fan K, et al. Among authors: blom a. Clin Cancer Res. 2018 Dec 1;24(23):5873-5882. doi: 10.1158/1078-0432.CCR-18-1184. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061360 Free PMC article.
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T. Brunot A, et al. Among authors: blom a. JAMA Dermatol. 2020 Sep 1;156(9):982-986. doi: 10.1001/jamadermatol.2020.2149. JAMA Dermatol. 2020. PMID: 32667663 Free PMC article.
Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed-death-receptor-1 monoclonal antibodies.
Charvet E, Kramkimel N, Chaplain L, Gantzer A, Kassem O, Longvert C, Blom A, Dupin N, Aractingi S, Hamon M, Zimmermann U, Emile JF, Sohier P, Sidibé T, Saiag P, Funck-Brentano E. Charvet E, et al. Among authors: blom a. Br J Dermatol. 2021 Apr;184(4):746-748. doi: 10.1111/bjd.19629. Epub 2020 Dec 1. Br J Dermatol. 2021. PMID: 33098566 No abstract available.
915 results